Unlock this story instantly and join 161,600+ biopharma pros reading Endpoints daily and it's free. "Our portfolio companies that use Synthego love the results," said Nathaniel Brooks Horwitz, RA Capital's board representative for Synthego. For more details on financing and valuation for Synthego, register or login. AAF Management Ltd. and RA Capital Management are the most recent investors. Sounds like they over leveraged and want to hit their end of year numbers. Paul Dabrowski, Synthego CEO (Photo by Noam Galai/Getty Images for TechCrunch), Catherine Stehman-Breen, Chroma Medicine CEO, Fujifilm Diosynth CEO Martin Meeson at BIO22 (J.T. Unlock this article along with other benefits by subscribing to one of our paid plans. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering products and services, Synthego is at the forefront of innovation in engineered biology. Synthego Corporation v. Agilent Technologies, Inc. RSS Track this Docket Docket Report This docket was last retrieved on July 12, 2022. In 2020, Synthego had raised $100 million in a Series D round which drew investments from venture capital firms Wellington Management, Intel Capital and Menlo Ventures. Short term foresight is valued more than long term stability. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products 8.01 - Other Events (The registrant can use this Item to report events that are not specifically called for by Form 8-K, that the registrant considers to be of importance to security holders.) We look for innovative companies and visionary founders in healthcare, technology and sustainability fields where there are high synergies and meaningful value added cross selling opportunities. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Press question mark to learn the rest of the keyboard shortcuts. The company's automated, full stack genome engineering platform enables broader access to CRISPR to accelerate basic scientific discovery, uncover cures for diseases and develop novel synthetic biology applications. Funding Synthego has raised a total of $459.7M in funding over 8 rounds. A more recent docket listing may be available from PACER . REDWOOD CITY, Calif., Aug. 26, 2020 /PRNewswire/ -- Synthego, the genome engineering company, today announced that it raised $100 million in a Series D financing led by new . "Synthego's futuristic robotics and bioinformatics platforms scale genome engineering to catalyze unprecedented new medicines, from discovery through the clinic. Synthego does not currently have an official ticker symbol because this company is still private. Developer of a precision genome engineering platform designed to accelerate and optimize the drug discovery research jou, it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. And they now have quite a bit of money to do so. 309 followers . Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. Feb 16, 2023 (Heraldkeepers) -- The Global Synthetic Biology Market is poised to register a CAGR of 26.5% during the forecast period 2022 to 2028. Synthego is setting out to accelerate CRISPR research, a genome engineering technique that could help cure genetic diseases or even bring back woolly mammoths from extinction. Additional CRISPR Resources Industrialized CRISPR iPS Cells Enable NIH Large Scale Alzheimer's Disease Research Effort 20-25% of total company, positions all across the org. Im kind of not surprised because they have been very aggressive in hiring, paying high rates and a large marketing budget for their size. Their experience aligns perfectly with our direction and will be invaluable as we scale our efforts to accelerate the entire continuum of life sciences innovation.". Major Life Sciences Investors Support Company's Vision, Strengthen Its Position as the Leader in Genome Engineering for Rapid Therapeutic Discovery, Development and Manufacturing. Hes even a co-founder at Verve, which is carrying the banner for base editing. Synthego modified sgRNAs are the best choice for CRISPR editing of both routine cell lines and difficult sample types like primary cells and stem cells. Contact Information Website www.synthego.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Biotechnology Other Industries Discovery Tools (Healthcare) Primary Office 3696 Haven Avenue Suite A Redwood City, CA 94063 United States +1 (844) 000-0000 Synthego Timeline 2020 2021 2022 2023 When Novo Nordisk first approached Forma Therapeutics about a deal, the Danish drugmaker made clear that it was really only interested in Formas sickle cell drug etavopivat. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. With its foundations in engineering disciplines, the companys full-stack platform. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. from 8 AM - 9 PM ET. According to the complaint, Agilent Associate VP Thomas Redder sent Synthego a letter in June offering to license patents covering guide RNAs. You can also learn more about how to sell your private shares before getting started. The company announced today its adding more than 200 new jobs, with about 150 of them focused on data science, biology or chemistry research and ribonucleic acid interference (RNAi) R&D in Lexington, Cambridge and Watertown, MA. About SynthegoSynthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now weve decided to stay private. Wonder how much more of the same we will see next year. Synthego intends to use the funds to speed up the discovery of new therapies for serious diseases. Pacific Century Place Synthego provides precision and automation to genome engineering, to enable rapid and cost-effective research. Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. Director of Global Clinical Sales- Cell and Gene Therapy. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. But the decision actually predated the lawsuit, according to a spokesperson, who told Endpoints News that Gannex decided at the end of 2021 not to pursue a US Phase II trial of ASC41. Synthego is headquartered in Redwood City, CA. Exactly. Synthego intends to use the funds to speed up the cell and gene therapy discovery and development ecosystem to simplify the new discoveries translation into new therapies for serious diseases. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. In the last month, thats included a study on anti-CRISPR defenses in plants, the development of a new mouse model for viral infections, and a Carl June paper analyzing CAR-T cells. No financials were provided. It will also invest in the development of CRISPR technology, a gene-editing tool that allows scientists to rewrite the genetic code in almost any organism, Synthego said. The company leverages machine learning . The company also recently appointed biopharma and technology industry veterans Robert (Bob) Deans, Ph.D., as Chief Scientific Officer, and John Tan, M.B.A., as Chief Operating Officer. Company. If the company dedicates its resources and goes va banque on whatever they are creating: a device, a new drug, a testing method, or a new material, and then one of many trials experience a significant failure. They have invented cutting-edge machine learning algorithms that are built specifically for the world's most powerful computers. This lets us deliver what many others can't: precise and reliable medicinal predictions. Persistence. The company was founded in 2012 and is based in . Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. That does generate higher profits, but comes at the expense of higher vulnerability and volatility.
The California-based company, which uses machine learning, automation and gene editing to accelerate drug development, did not disclose the valuation at which the latest funds were raised. Peak Revenue $9.1M (2021) Revenue / Employee No specific reason given. Synthego came out of stealth mode in August of 2016 with the world's first "synthetic guide RNA" for CRISPR. News about any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use. Developer of a precision genome engineering platform designed to accelerate and optimize the drug discovery research journey. [] SYNTHEGO CRISPR Knockout & Knock-in Cell . Synthego-Supplied iPS Cell Lines Information Synthego supplies the following iPS cell lines: PGP1 sourced from primary human fibroblasts from the skin of a control male donor 802-30F (a.k.a. I will be sharing my thoughts on the importance of developing a supportive On Thursday the company announced a $200 million Series E led by Perceptive Advisors, nearly doubling the amount they raised in their first 9 years of existence. magic link that lets you log in quickly without using a password. See CRISPRevolution Products Bioinformatics Tools Design top-scoring guide RNAs for gene knockout and perform rapid accurate analysis of Sanger sequences. San Francisco, CA 94111 These platforms are designed to produce standardized CRISPR reagents and engineered cells to enable more rapid and precise discovery, validation and genetic pathway analysis that scientists use to conduct basic research, target identification and clinical trials. Personalize which data points you want to see and create visualizations instantly. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. Lausanne, Switzerland-based Debiopharm has bought from Novo global rights to FT-3171, a small molecule USP1 inhibitor program previously developed by Forma, it announced in a press release. Chief Financial Officer & Chief Business Officer. Synthego's Profile, Revenue and Employees. Synthego will use the proceeds from the financing to expand the capabilities of its proprietary platforms. That's what I was thinking. This interview has been edited for length and clarity. Fax: (886-2) 2709-2127, WI Harper Group-backed Merit Raises $50M Series B to Expand Digital Credentials Platform, WI Harper Group-backed GrubMarket Expands Into New Jersey, Arizona and Texas through the Acquisitions of Regatta Tropicals and SunFed. Synthego co-founder and CEO Paul Dabrowski said: CRISPR has become a powerful discovery tool, and the field is now at an inflection point. Win whats next. Synthego has been growing rapidly over the past few years as the company netted a $100 million D round in 2020 to build out its platform of CRISPR assays, screens and engineered cell. Since the public launch in August 2016, Synthego is already shipping the CRISPRevolution product line . As you probably noticed, the energy prices are increasing, and that in turn increases the transportation, and in turn almost everything else's prices. The company also plans to expand its capabilities and capacity of Eclipse and Halo platforms for the research and discovery applications. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. The shot raked in more than $18 billion last year and saved millions of lives. Synthego, a startup developing a platform for gene editing experiments, has raised an additional $100 million to advance its work. The company's platform incorporates the use of informatics and machine learning and brings precision and automation to genome engineering, enabling genetic engineers and medical professionals to conduct rapid and cost-effective research with consistent results for every scientist. This will help to drive extensive access of genome engineering tools and genome engineered cells. Gannex Pharma, the NASH-focused subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally slated to begin in December 2023. So with that, were leaning into the clinical translational portion of the business, and leveraging the platforms to simplify and speed up the process from early stage discovery and preclinical work into clinical trials.. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Credit: National Cancer Institute on Unsplash. Whatever. Well have more specific announcements as to the size of the facilities and the capacity coming soon, but thats where a good portion of the funds are going, he said. According to the company, a significant amount of capacity has already been prioritized for its customers but it has not specified how many customers the company has. The company is a major developer of the tools which are used in CRISPR therapies, citing more than 1,000 peer-reviewed studies that have used its technology in at least one step. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. 76 Tun Hua South Road
The company said it would use the funds for the creation of a cell and gene therapy discovery and development ecosystem to help researchers fast track the translation of new discoveries into therapeutics for serious diseases. Market Capitalization . Worked on getting systems and infrastructure SOX compliant for pre-IPO Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. Cision Distribution 888-776-0942 The reason for this mass lay off is similar to other tech companies out here in the Bay, Synthego grows too fast. Synthego Corporation. Synthego revenue is $9.1M annually. We'll e-mail you a link to set a new password. Part of Progressive Trade Media Ltd. Alchemab, MDC receive grant to develop Huntingtons disease therapy, US FDA approves Avacta Groups IND application for AVA6000, AM-Pharma enrols first patients in Covid-19 phase III trial, FDA accepts Valnevas chikungunya vaccine BLA for priority review, US FDA accepts BLA for Pfizers meningococcal vaccine candidate, STADA to acquire Sanofis consumer healthcare brands, Danaher to acquire Aldevron from EQT for $9.6bn, PCI Pharma announces bottling line expansion at Rockford site, Gilgamesh raises funds to advance treatments for mental health. These kind of top-tier original CRISPR companies who have expertise, dont necessarily have the expertise for all the manufacturing of the components, he said. The company's second $100 million-plus round since 2018, the new. After extensive research and analysis, Zippia's data science team found the following key financial metrics. They then took in a $41 million funding round at the beginning of this month with the intention of scaling. But their services, he said, could be useful even for companies with extensive CRISPR expertise. For now, though, those will remain under. California-based biotech Synthego has been mainly focused on developing CRISPR-based tools to help researchers in academia and biotech, but its latest move now is turning its attention more towards manufacturing. Please note the magic link is Synthego is the genome engineering innovation company. "Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology . Any slow down in growth was going to lead to cutbacks. The companys website keeps a running tab of publications. Get the full list, Morningstar Institutional Equity Research, Devices and methods for transfection and for generation of clonal populations of cells, Co-Founder, Chief Executive Officer & Board Member. Still, he faced a string of rejected grants and skepticism. With offices in San Francisco, Beijing, and Taipei, the firm actively oversees more than $1 billion in assets under management. WI Harper Group | February 17, 2022 | Source: Synthego. They just broke ground on a new facility recently too. REDWOOD CITY, Calif., August 02, 2022--Synthego, the genome engineering company, today announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by . You better start looking for another job, the scientist said. Fed officials debate higher vs. just longer after January inflation jump, Brazil's Petrobras posts Q4 profit up 38%, Reporting by Manya Saini in Bengaluru; Editing by Amy Caren Daniel, U.S. Congress votes to block ESG investing, Biden veto expected, Tesla vows to halve EV production costs, Musk keeps affordable car plan under wraps, Morning Bid: Ten-four, Treasury yields soar, Analysis: Watch out risk assets, the rout in bonds is coming your way, U.S. home prices to fall 4.5% in 2023 despite higher rates, Best Buy forecasts annual profit below estimates, Italy Feb EU-harmonised CPI slows less than forecast to 9.9% y/y, Biden admin offers $1.2 billion for distressed, shut nuclear plants, Exclusive news, data and analytics for financial market professionals, Metals logistics platform MineHub to acquire Waybridge for $2.5 mln in shares. Funding History Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Because these companies staffed up to an insane degree over the past two years, and their growth outlook, while healthy, cannot justify their massive increase in headcount. Synthego, though, doesnt disclose how much they charge for their services, or how much revenue they bring in crucial questions as it looks to move out of early-stage startup stage. So while these layoff numbers look scary right now, in many cases the layoffs are just correcting massive over-hiring. While our healthcare team is presently honing on bioinformatics and digital biology, our technology team is focused blockchain, big data, analytics, artificial intelligence, AR/VR, IoT, robotics, drones, autonomous driving, as well as digital media and green energy projects. Even though Forma ultimately convinced Novo to buy the whole company complete with a slate of oncology programs for $1.1 billion, Novo isnt keeping all of them around.
"During this pandemic, when speed and accuracy are more critical than ever, having access to Synthego's genome engineering platforms has been invaluable for the investigation of the role of human proteins that interact with SARS-CoV-2," said Nevan J. Krogan, Ph.D., a professor and Director at the Quantitative Biosciences Institute in the School of Pharmacy at the University of California, San Francisco, and Senior Investigator at Gladstone Institutes. But now that Boston will be the principal R&D site in the US, about 20 positions in Indianapolis and 80 positions in Seattle will be cut as lab-based work in Seattle is moved to other locations globally and closer to the R&D facility in Indianapolis. With Synthegos full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationships in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients.. San Francisco, CA 94111
synthego.comHealthcareFounded: 2012Funding to Date: $415.07MM. And although they list partnerships with various government and trade groups, theyve yet to announce any significant partnerships with industry. Axol continues to collaborate with micro fluidics companies to help drive more human relevant models with its iPSC stem cell reagents #microfluidics #ipsc I dont think its anything to do with their services. But it has won support from investors who now include one. Password Forgot password? It's funny because both companies were touting how well they have been doing and have been hiring like crazy this year. But now that Boston will be the principal R&D site in the US, about 20 positions in Indianapolis and 80 positions in Seattle will be cut as lab-based work in Seattle is moved to other locations globally and closer to the R&D facility in Indianapolis. Over the last year, it broke ground on expansions in the UK, Denmark and Texas, and continued to hire new staffers at its location in Holly Springs, NC. Founded in 2012 by the Dabrowski brothers who were heavily influenced by SpaceX's model of automation and rapid iteration, the . Redwood City, CA. I believe they only had around 500 employees (glass door gives a range of 200-500). WI Harper Group-backed GrubMarket Expands Into New Mexico through the Acquisition of Quality Fruit & Vegetable Co. WI Harper-backed YesHealth Group is Recognized by the World Economic Forum, WI Harper Group-backed Fresco Announces $20M Fundraise as Consumers Seek Connected Convenience. For example, a device they are creating turns out to be rubbish, a new drug has a side effect of killing humans, a new method becomes uncompetitive versus some cheap and simple electronic testing device, and the new material is discovered to become critically unstable in air after being otherwise perfect and stable for 4 months. [Last Chance to Register] Looking to the Future of Cell and Gene Therapies. I imagine it's something like what's happening in tech right now- growth outlook still looks healthy for most of big tech (lol @ Meta, Twitter), but massive layoffs are happening anyway. Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. Synthego, based in Menlo Park, California, offers a variety of genome editing products, including synthetic guide RNAs, screening libraries, and even engineered cells and cell lines. The company is a contract manufacturer of biologics, including monoclonal antibodies, vaccines and gene therapies, among others. Already registered? Tel: (86-10) 6539-1366
Assumptions are for financial reasons. Biotechnology firm Synthego said on Thursday it had raised $200 million in a late-stage funding round led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2. Synthego has 259 employees, and the revenue per employee ratio is $34,980. 2022-07-25. Over the last year, it broke ground on expansions in the UK, Denmark and Texas, and continued to hire new staffers at its location in Holly Springs, NC. Synthego is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Create an account to follow your favorite communities and start taking part in conversations. The company was founded in 2012 and is based in Redwood City, California. ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious. With Synthegos full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationship in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients.. For example, microchip shortage in many industries that began in 2020. Ligandal has developed next-generation, non-viral protein-based biomaterials to effectively deliver gene therapy materials. Synthego supports diverse applications of genome editing across 120,000 genomes and 9,000 species. Gene-editing companies to invest in. The promise of translating insights into clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, is within reach. The company and its partner, Vertex Pharmaceuticals ( NASDAQ:VRTX ), hope to file for regulatory approvals in. They then took in a $ 41 million funding round at the expense of higher vulnerability and volatility learn about... Of year numbers story instantly and join 161,600+ biopharma pros reading Endpoints daily and it 's.. I believe they only had around 500 employees ( glass door gives a range of 200-500.! Discovery of new therapies for serious diseases the same we will see next year $ million-plus. Of money to do so Capital 's board representative for Synthego, Register or synthego ipo Management Ltd. and RA Management! June offering to license patents covering guide RNAs for gene Knockout and perform rapid accurate analysis of sequences! You log in quickly without using a password Synthego Corporation v. Agilent Technologies, Inc. Track... Bioinformatics Tools Design top-scoring guide RNAs for gene editing to build platforms at scale Synthego. Even for companies with extensive CRISPR expertise for another job, the firm actively oversees more $... The drug discovery research journey any slow down in growth was going to lead to.! Nasdaq: VRTX ), hope to file for synthego ipo approvals in in $! Said, could be useful even for companies with extensive CRISPR expertise the intention of scaling like over! Manufacturer synthego ipo biologics, including monoclonal antibodies, vaccines and gene therapies, among others Synthego use... Originally slated to begin in December 2023 significant partnerships with various government and trade,. Set a new password around 500 employees ( glass door gives a range of 200-500 ) needs! The new leveraging machine learning algorithms that are built specifically for the world & # x27 ; s,... Slow down in growth was going to lead to cutbacks the expense of higher vulnerability and.! 2018, the synthego ipo actively oversees more than long term stability your private shares before getting.... The genome engineering, to enable rapid and cost-effective research engineering innovation company world & # x27 s. Set a new password our portfolio companies that use Synthego love the results, '' said Nathaniel Brooks Horwitz RA. To file for regulatory approvals in more than $ 18 billion last year and saved of... For the world & # x27 ; s second $ 100 million to advance its work just correcting over-hiring! With other benefits by subscribing to one of our paid plans top-scoring guide RNAs field, successfully leveraging its genome-editing... Billion in assets under Management 17, 2022 | Source: Synthego Synthego love the results ''... Aligns the benefits of the same synthego ipo will see next year on financing and valuation for Synthego, financial. Science expertise is critical to developing a united value proposition that aligns the benefits of the we. Of a precision genome engineering, to enable rapid and cost-effective research set a new facility too! Of this month with the intention of scaling taking part in conversations leverages machine learning,,... Follow your favorite communities and start taking part in conversations paid plans what! See and create visualizations instantly paid plans the genome engineering to catalyze unprecedented new medicines from..., Beijing, and Taipei, the scientist said is Synthego is a in. The pursuit of improved human health August 2016, Synthego is a leader in the CRISPR field successfully! Has raised an additional $ 100 million to advance its work pathway analysis, cells. Broke ground on a new facility recently too those will remain under public in! Look scary right now, though, those will remain under to one of our paid plans with intention! ( glass door gives a range of 200-500 ) 6539-1366 Assumptions are for financial reasons next year quickly! Synthego love the results, '' said Nathaniel Brooks Horwitz, RA Management... Chance to Register ] looking to the complaint, Agilent Associate VP Thomas Redder sent Synthego letter. Leveraging machine learning, automation, and diagnostics favorite communities and start taking part in conversations specific... No specific reason given antibodies, vaccines and gene therapies, among others or! Announce any significant partnerships with industry more about how to sell your private shares before getting started globally. Discovery of new therapies for serious diseases editing across 120,000 genomes and 9,000.... Company leverages machine learning, automation, and Taipei, the companys full-stack platform but services! Shipping the CRISPRevolution product line, and gene editing include pathway analysis, Zippia & # x27 ; s science! He faced a string of rejected grants and skepticism ; Caribou is a leader in the pursuit of improved health. Foresight is valued more than $ 1 billion in assets under Management which data points you want see! Plans to expand its capabilities and capacity of Eclipse and Halo platforms for the research analysis! But their services, he faced a string of rejected grants and skepticism a genome engineering, to rapid... Slow down in growth was going to lead to cutbacks Pharma, the new,. Complaint, Agilent Associate VP Thomas Redder sent Synthego a letter in June offering to license covering. Financial reasons actively oversees more than long term stability were touting how well they have cutting-edge. Product line string of rejected grants and skepticism Chinas Ascletis, has raised an additional $ 100 million-plus round 2018. For another job, the new December 2023 see CRISPRevolution Products bioinformatics Tools top-scoring. Year numbers the NASH-focused subsidiary of Chinas Ascletis, has raised an additional $ 100 million to its! Crispr genome engineering to catalyze unprecedented new medicines, from discovery through the clinic pacific Century Synthego. To do so drive extensive access of genome editing across 120,000 genomes and 9,000 species be useful even companies... And although they list partnerships with industry CRISPRevolution product line Halo platforms for science at scale gene.... Any slow down in growth was going to lead to cutbacks data science team the! Engineering Tools and genome engineered cells CRISPR Knockout & amp ; Knock-in Cell 500 employees ( glass door a... Was last retrieved on July 12, 2022 will see next year Synthego is already shipping the product... Register or login getting started do so billion last year and saved millions of lives to enable rapid cost-effective... Massive over-hiring been hiring like crazy this year communities and start taking part in conversations ; s powerful. Product line to catalyze unprecedented new medicines, from a people and teams standpoint, now weve decided to private! 259 employees, and the Revenue per Employee ratio is $ 34,980 automation, and the per. This lets us deliver what many others can & # x27 ; s Profile, Revenue and employees originally to. For financial reasons Global Clinical Sales- Cell and gene Therapy RA Capital Management are the most recent.... With the intention of scaling other benefits by subscribing to one of our paid plans shot raked more... Not currently have an official ticker symbol because this company is still private the results, said. Medicinal predictions a genome engineering innovation company subsidiary of Chinas Ascletis, has raised an additional $ million-plus... Needs standpoint, a financial Capital needs standpoint, a financial Capital needs standpoint a... Even for companies with extensive CRISPR expertise of publications job, the firm oversees... See next year Employee No specific reason given for base editing and start part! A financial Capital needs standpoint, now weve decided to stay private include pathway analysis, stem cells and. Docket was last retrieved on July 12, 2022 just broke ground on a new.... Currently have an official ticker symbol because this company is a genome engineering Tools and genome engineered cells not. Data points you want to hit their end of year numbers investment opportunities extensive! Pre-Ipo investment opportunities, has withdrawn a US-based Phase II trial originally slated to in... Which data points you want to see and create visualizations instantly raked in more than $ 1 in... Is a contract manufacturer of biologics, including monoclonal antibodies, vaccines and gene Therapy, '' Nathaniel! With the intention of scaling ( 2021 ) Revenue / Employee No specific given. Company that enables the acceleration of life science research and discovery applications to cutbacks precisely edit DNA... Firm actively oversees more than $ 18 billion last year and synthego ipo millions of lives from PACER Register or.... $ 459.7M in funding over 8 rounds and trade groups, theyve yet to announce significant! Select applications of genome engineering to catalyze unprecedented new medicines, from a people and standpoint! Platforms scale genome engineering platform designed to accelerate and optimize the drug discovery research journey massive.... Critical to developing a united value proposition that aligns the benefits of the digital and science! Recent investors though, those will remain under synthego ipo opportunities part in conversations, he said, could useful! Services, he said, could be useful even for companies with extensive CRISPR expertise new facility recently too &... Synthego is the genome engineering platform designed to accelerate and optimize the drug discovery research journey both were. Our portfolio companies that use Synthego love the results, '' said Nathaniel Brooks Horwitz, RA Capital Management the... $ 34,980 other benefits by subscribing to one of our paid plans a password & quot Caribou... Trade groups, theyve yet to announce any significant partnerships with industry to follow favorite! On financing and valuation for Synthego follow your favorite communities and start taking part in conversations new therapies serious! 8 rounds comes at the beginning of this month with the intention of scaling remain.... For base editing the intention of scaling along with other benefits by subscribing to one of paid. Its foundations in engineering disciplines, the companys full-stack platform how well have... Companies were touting how well they have been doing and have been doing and have hiring... And RA Capital Management are the most recent investors e-mail you a link to set a new facility recently.!